HRP20171805T1 - Derivati 17-hidroksi-17-pentafluoroetil-estra-4,9(10)-dien-11-arila, postupci za njihovu proizvodnju i njihova upotreba za liječenje bolesti - Google Patents
Derivati 17-hidroksi-17-pentafluoroetil-estra-4,9(10)-dien-11-arila, postupci za njihovu proizvodnju i njihova upotreba za liječenje bolesti Download PDFInfo
- Publication number
- HRP20171805T1 HRP20171805T1 HRP20171805TT HRP20171805T HRP20171805T1 HR P20171805 T1 HRP20171805 T1 HR P20171805T1 HR P20171805T T HRP20171805T T HR P20171805TT HR P20171805 T HRP20171805 T HR P20171805T HR P20171805 T1 HRP20171805 T1 HR P20171805T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- estra
- dien
- hydroxy
- pentafluoroethyl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 32
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 201000009273 Endometriosis Diseases 0.000 claims 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 230000035558 fertility Effects 0.000 claims 3
- 229940088597 hormone Drugs 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 201000010260 leiomyoma Diseases 0.000 claims 3
- 229940127554 medical product Drugs 0.000 claims 3
- 206010027191 meningioma Diseases 0.000 claims 3
- 208000007106 menorrhagia Diseases 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 101100533890 Hypocrea jecorina (strain QM6a) sor3 gene Proteins 0.000 claims 1
- 101100533874 Hypocrea jecorina (strain QM6a) sor5 gene Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (33)
1. Spoj s formulom I
[image]
naznačen time da
R1predstavlja ili ostatak Y ili predstavlja fenilni prsten supstituiran jednom ili dva puta s ostatkom Y,
Y je odabran iz skupine koja sadrži SR2, S(O)R3, S(O)2R3, S(O)(NH)R3, S(O)(NR4)R3, S(O)2NR9R10,
R2predstavlja vodik, C1-C6-alkil, C7-C10-aralkil ili aril,
R3predstavlja C1-C6-alkil ili aril,
R4predstavlja skupinu S(O)2R6,
R6 predstavlja fenil ili 4-metilfenil
X označava kisikov atom, NOR7 ili NNHSO2R7,
R7je odabran iz skupine koja sadrži vodik, C1-C10-alkil, aril
R9, R10su neovisno jedan od drugoga odabrani iz skupine koja sadrži vodik, C1-C10-alkil ili aril ili alternativno predstavljaju, zajedno s dušikovim atomom, 3- do 8-člani, zasićeni ili nezasićeni heterociklički prsten,
i njihovi odvojeni stereoizomeri, njihove soli, solvati ili solvati soli, uključujući sve kristalne modifikacije.
2. Spoj prema zahtjevu 1, naznačen time da
R1predstavlja ili ostatak Y ili fenilni prsten supstituiran jednom s ostatkom Y,
Y je odabran iz skupine koja sadrži SR2, S(O)R3, S(O)2R3, S(O)(NH)R3, S(O)(NR4)R3, S(O)2NR9R10 i
R2predstavlja vodik ili C1-C6-alkil,
R3predstavlja C1-C6-alkil i
X predstavlja kisikov atom,
R6predstavlja fenil ili 4-metilfenil i
R9, R10neovisno jedan od drugoga predstavljaju vodik ili C1-C6-alkil ili fenil
i njihovi odvojeni stereoizomeri, njihove soli, solvati ili solvati soli.
3. Spoj prema zahtjevu 1, naznačen time da R1predstavlja S(O)2R3i X predstavlja O.
4. Spoj prema zahtjevu 3, naznačen time da R3predstavlja C1-C6-alkil.
5. Spoj prema zahtjevu 1, naznačen time da R1predstavlja S(O)(NH)R3i X predstavlja O i njihovi odvojeni stereoizomeri.
6. Spoj prema zahtjevu 5, naznačen time da R3predstavlja C1-C6-alkil i njihovi odvojeni stereoizomeri.
7. Spoj prema zahtjevu 6, naznačen time da R3predstavlja metil i njihovi odvojeni stereoizomeri.
8. Spoj prema zahtjevu 1, naznačen time da R1predstavlja SOR3 i X predstavlja O i njihovi odvojeni stereoizomeri.
9. Spoj prema zahtjevu 8, naznačen time da R3predstavlja C1-C6-alkil i njihovi odvojeni stereoizomeri.
10. Spoj prema zahtjevu 9, naznačen time da R3predstavlja metil i njihovi odvojeni stereoizomeri.
11. Spoj prema zahtjevu 1, naznačen time da R1predstavlja SR2 i X predstavlja O.
12. Spoj prema zahtjevu 11, naznačen time da R2predstavlja vodik.
13. Spoj prema zahtjevu 11, naznačen time da R2predstavlja C1-C6-alkil.
14. Spoj prema zahtjevu 13, naznačen time da R2predstavlja metil.
15. Spoj prema zahtjevu 11, naznačen time da R2predstavlja aril.
16. Spoj prema zahtjevu 15, naznačen time da R2predstavlja fenil.
17. Spoj prema zahtjevu 11, naznačen time da R2predstavlja C7-C10-aralkil.
18. Spoj prema zahtjevu 17, naznačen time da R2predstavlja benzil.
19. Spojevi prema zahtjevu 2, naznačeni time da R2predstavlja metil, etil ili vodik.
20. Spojevi prema zahtjevu 1, naznačeni time da R3predstavlja C1-C6-alkil.
21. Spojevi prema zahtjevu 4, naznačeni time da R3predstavlja metil ili etil.
22. Spojevi prema zahtjevu 1, naznačeni time da R6predstavlja fenil.
23. Spojevi prema zahtjevu 1, naznačeni time da X je kisikov atom.
24. Spojevi prema zahtjevu 1, naznačeni time da Y predstavlja SR2ili S(O)2R3ili S(O)(NH)R3 gdje je R2jednak vodiku, metilu ili etilu i R3je jednak metilu ili etilu.
25. Spojevi prema zahtjevu 1, naznačeni time da Y predstavlja S(O)2R3.
26. Spojevi prema zahtjevu 1 naznačeni time da su
(11β,17β)-17-hidroksi-11-[4-(metilsulfanil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-on;
(11β,17β)-11-[4-(etilsulfanil)fenil]-17-hidroksi-17-(pentafluoroetil)estra-4,9-dien-3-on;
(11β,17β)-17-hidroksi-11-{4-[(RS)-metilsulfinil]fenil}-17-(pentafluoroetil)estra-4,9-dien-3-on;
(11β,17β)-11-[4-(etilsulfonil)fenil]-17-hidroksi-17-(pentafluoroetil)estra-4,9-dien-3-on;
(11β,17β)-11-[4-(benzilsulfanil)fenil]-17-hidroksi-17-(pentafluoroetil)estra-4,9-dien-3-on;
N-[{4-[(11β,17β)-17-hidroksi-3-okso-17-(pentafluoroetil)estra-4,9-dien-11-il]fenil}(RS)(metil)oksido-λ6-sulfaniliden]-4-metilbenzen sulfonamid;
(11β,17β)-17-hidroksi-11-[4-(RS-metilsulfonimidoil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-on;
(11β,17β)-17-hidroksi-11-[4'-(metilsulfanil)bifenil-4-il]-17-(pentafluoroetil)estra-4,9-dien-3-on;
(11β,17β)-17-hidroksi-11-[4'-(metilsulfonil)bifenil-4-il]-17-(pentafluoroetil)estra-4,9-dien-3-on;
N-[{4'-[(11β,17β)-17-hidroksi-3-okso-17-(pentafluoroetil)estra-4,9-dien-11-il]bifenil-4-il}(RS)(metil)oksido-λ6-sulfaniliden]-4-metilbenzen sulfonamid;
(11β,17β)-17-hidroksi-11-[4'-(RS-metilsulfonimidoil)bifenil-4-il]-17-(pentafluoroetil)estra-4,9-dien-3-on;
(11β,17β)-17-hidroksi-17-(pentafluoroetil)-11-(4'-sulfanilbifenil-4-il)estra-4,9-dien-3-on;
4'-[(11β,17β))-17-hidroksi-3-okso-17-(pentafluoroetil)estra-4,9-dien-11-il]-N,N-dimetilbifenil-4-sulfonamid;
4-[(11β,17β)-17-hidroksi-3-okso-17-(pentafluoroetil)estra-4,9-dien-11-il]-N,N-dimetilbenzen sulfonamid
27. Spoj prema jednom od prethodnih zahtjeva, naznačena time da je za liječenje i sprječavanje bolesti.
28. Spoj prema jednom od zahtjeva 1-26, naznačena time da je za liječenje i sprječavanje mioma maternice, endometrioze, teškog menstrualnog krvarenja, meningioma, karcinoma dojke ovisnih o hormonima i pritužbi povezanih s menopauzom ili za kontrolu plodnosti i kontracepciju u hitnim slučajevima.
29. Uporaba spoja prema jednom od zahtjeva 1-26, naznačena time da je za proizvodnju medicinskog proizvoda za liječenje i/ili sprječavanje bolesti.
30. Uporaba spoja prema jednom od zahtjeva 1-26, naznačena time da je za proizvodnju medicinskog proizvoda za liječenje i/ili sprječavanje mioma maternice, endometrioze, teškog menstrualnog krvarenja, meningioma, karcinoma dojke ovisnih o hormonima i pritužbi povezanih s menopauzom ili za kontrolu plodnosti i kontracepciju u hitnim slučajevima.
31. Medicinski proizvod naznačen time da sadrži spoj kako je definiran u jednom od zahtjeva 1-26, u kombinaciji s drugom aktivnom tvari.
32. Medicinski proizvod naznačen time da sadrži spoj kako je definiran u jednom od zahtjeva 1-26, u kombinaciji s inertnim, ne-toksičnim, farmaceutski prihvatljivim pomoćnim sredstvom.
33. Medicinski proizvod prema zahtjevima 31 ili 32 naznačen time da je za liječenje i/ili sprječavanje mioma maternice, endometrioze, teškog menstrualnog krvarenja, meningioma, karcinoma dojke ovisnih o hormonima i pritužbi povezanih s menopauzom ili za kontrolu plodnosti i kontracepciju u hitnim slučajevima.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102009034362A DE102009034362A1 (de) | 2009-07-20 | 2009-07-20 | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
EP12194455.7A EP2623510B1 (de) | 2009-07-20 | 2010-07-07 | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171805T1 true HRP20171805T1 (hr) | 2017-12-29 |
Family
ID=43383964
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20130558AT HRP20130558T1 (hr) | 2009-07-20 | 2013-06-18 | Derivat 17-hidroksi-17-pentafluoretil-estra-4,9(10)-dien-11-arila, postupci za njegovu proizvodnju i njegova uporaba za lijeäśenje bolesti |
HRP20171805TT HRP20171805T1 (hr) | 2009-07-20 | 2017-11-21 | Derivati 17-hidroksi-17-pentafluoroetil-estra-4,9(10)-dien-11-arila, postupci za njihovu proizvodnju i njihova upotreba za liječenje bolesti |
HRP20191049TT HRP20191049T1 (hr) | 2009-07-20 | 2019-06-12 | (11beta, 17beta)-17-hidroksi-11-[4-(metilsulfonil)fenil]-17-(pentalfuorometil)estra-4,9-dien-3-on za uporabu za liječenje bolesti |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20130558AT HRP20130558T1 (hr) | 2009-07-20 | 2013-06-18 | Derivat 17-hidroksi-17-pentafluoretil-estra-4,9(10)-dien-11-arila, postupci za njegovu proizvodnju i njegova uporaba za lijeäśenje bolesti |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191049TT HRP20191049T1 (hr) | 2009-07-20 | 2019-06-12 | (11beta, 17beta)-17-hidroksi-11-[4-(metilsulfonil)fenil]-17-(pentalfuorometil)estra-4,9-dien-3-on za uporabu za liječenje bolesti |
Country Status (48)
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009034367A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034362A1 (de) * | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034525A1 (de) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034526A1 (de) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
DE102010007719A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
DE102011088270A1 (de) | 2011-12-12 | 2013-06-13 | Bayer Intellectual Property Gmbh | (11ß ,17ß)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot Marie Toot |
EP2983671B1 (en) * | 2013-04-11 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Progesterone receptor antagonist dosage form |
US9096641B2 (en) | 2013-06-05 | 2015-08-04 | Evestra, Inc. | Imidazolyl progesterone antagonists |
JP2018515551A (ja) * | 2015-05-18 | 2018-06-14 | バイエル・ファルマ・アクティエンゲゼルシャフト | 選択的プロゲステロン受容体モジュレーター(sprm)レジメン |
EP3214092A1 (en) | 2016-03-04 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one |
EP3384913A1 (en) * | 2017-04-03 | 2018-10-10 | Bayer Pharma Aktiengesellschaft | Selective progesterone receptor modulators and stabilized estrogen level in patient |
EP3701951A4 (en) * | 2017-10-26 | 2020-09-16 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTAL SHAPE OF SELECTIVE PROGESTERONE RECEPTOR MODULATORS AND PROCESS FOR THEIR PRODUCTION |
WO2023167878A1 (en) | 2022-03-01 | 2023-09-07 | Altin Biosciences Corporation | Crila® and egcg compositions for treatment of fibroids |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA8231B (en) | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
DE3347126A1 (de) * | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
FR2596395B1 (fr) * | 1986-03-26 | 1989-05-26 | Roussel Uclaf | Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
US5272140A (en) | 1987-01-23 | 1993-12-21 | Akzo N.V. | 11-aryl steroid derivatives |
FR2620707B1 (fr) | 1987-09-18 | 1989-12-08 | Roussel Uclaf | Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
FR2644789B1 (fr) | 1989-03-22 | 1995-02-03 | Roussel Uclaf | Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
DK0411733T3 (da) | 1989-08-04 | 1999-06-28 | Schering Ag | 11-beta-aryl-gona-4,9-dien-3-oner |
US5407928A (en) | 1990-08-15 | 1995-04-18 | Schering Aktiengesellschaft | 11β-aryl-gona-4,9-dien-3-ones |
CA2100514C (en) * | 1992-07-29 | 2005-03-29 | Johannes A. M. Hamersma | 17-spiromethylene steroids |
FR2718354B1 (fr) | 1994-04-08 | 1996-05-03 | Roussel Uclaf | Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant. |
DE4426601A1 (de) | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
ES2218556T3 (es) | 1994-11-22 | 2004-11-16 | Balance Pharmaceuticals, Inc. | Metodos de contracepcion. |
HU230492B1 (hu) | 1996-05-01 | 2016-08-29 | The Government Of The United States Of America | Új progesztációt gátló szerként használható 21-helyzetben szubsztituált progeszteron-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk |
WO1998005679A2 (en) | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
FR2757400B1 (fr) | 1996-12-19 | 1999-12-17 | Hoechst Marion Roussel Inc | Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs |
DE19706061A1 (de) | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
US20010016578A1 (en) | 1997-06-18 | 2001-08-23 | Balance Pharmaceuticals, Inc. | Compositions and methods for contraception and for treatment of benign gynecological disorders |
JPH11171774A (ja) | 1997-12-05 | 1999-06-29 | Kyowa Hakko Kogyo Co Ltd | 血球増多剤 |
PE20000129A1 (es) | 1997-12-23 | 2000-03-11 | Schering Ag | 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa |
US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
WO1999053924A1 (fr) | 1998-04-17 | 1999-10-28 | Kyowa Hakko Kogyo Co., Ltd. | Agent analgesique |
US6172052B1 (en) * | 1998-12-04 | 2001-01-09 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
US6476079B1 (en) | 1999-12-23 | 2002-11-05 | Leiras Oy | Devices for the delivery of drugs having antiprogestinic properties |
EP1157996A1 (de) | 2000-05-23 | 2001-11-28 | JENAPHARM GmbH | Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on |
JP2004509131A (ja) | 2000-09-18 | 2004-03-25 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 21−ヒドロキシ−6,19−オキシドプロゲステロン(21oh−6op)の製造方法 |
DE10051609A1 (de) | 2000-10-18 | 2002-05-02 | Schering Ag | Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen |
ES2272561T3 (es) | 2000-10-18 | 2007-05-01 | Schering Aktiengesellschaft | Inhibicion de dependencia de factores de crecimiento de la celulas tumorales. |
US7378406B2 (en) | 2000-10-18 | 2008-05-27 | Schering Ag | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
CN1244329C (zh) * | 2001-01-09 | 2006-03-08 | 舍林股份公司 | 抗促孕素在制备用于抑制雌性哺乳动物中发生子宫内膜加速成熟的药物中的应用 |
US20020143000A1 (en) * | 2001-01-09 | 2002-10-03 | Christa Hegele-Hartung | Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment |
DE10159217A1 (de) | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
DE50301507D1 (de) | 2002-05-03 | 2005-12-01 | Schering Ag | 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN |
DE10221034A1 (de) | 2002-05-03 | 2003-11-20 | Schering Ag | 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
MX2007000273A (es) | 2004-07-09 | 2007-05-21 | Population Council Inc | Composiciones de liberacion sostenida que contiene moduladores del receptor de progesterona. |
WO2006101009A1 (ja) | 2005-03-18 | 2006-09-28 | Hirose Engineering Co., Ltd. | ナイルレッド系赤色発光化合物、及び発光素子 |
US20070105828A1 (en) | 2005-08-19 | 2007-05-10 | Glenmark Pharmaceuticals Limited | Novel polymorph form M of mifepristone and process for its preparation |
EP1862468A1 (de) | 2006-06-02 | 2007-12-05 | Bayer Schering Pharma Aktiengesellschaft | Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on |
DE102006054535A1 (de) | 2006-11-15 | 2008-05-21 | Bayer Schering Pharma Aktiengesellschaft | Progesteronrezeptorantagonisten |
US20090075989A1 (en) * | 2006-12-21 | 2009-03-19 | Wolfgang Schwede | Non-steroidal progesterone receptor modulators |
WO2008105876A1 (en) | 2007-03-01 | 2008-09-04 | Prs Mediterranean Ltd. | Uv resistant multilayered cellular confinement system |
EP2123279A1 (de) | 2008-05-14 | 2009-11-25 | Bayer Schering Pharma Aktiengesellschaft | Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen |
DE102009034362A1 (de) * | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
-
2009
- 2009-07-20 DE DE102009034362A patent/DE102009034362A1/de not_active Withdrawn
-
2010
- 2010-07-07 EP EP10735198A patent/EP2432798B1/de active Active
- 2010-07-07 HU HUE17176264A patent/HUE043757T2/hu unknown
- 2010-07-07 SI SI201030255T patent/SI2432798T1/sl unknown
- 2010-07-07 DK DK12194455.7T patent/DK2623510T3/en active
- 2010-07-07 ES ES17176264T patent/ES2730209T3/es active Active
- 2010-07-07 LT LTEP17176264.4T patent/LT3252069T/lt unknown
- 2010-07-07 TR TR2019/08600T patent/TR201908600T4/tr unknown
- 2010-07-07 LT LTEP12194455.7T patent/LT2623510T/lt unknown
- 2010-07-07 ME MEP-2019-131A patent/ME03400B/me unknown
- 2010-07-07 SI SI201031890T patent/SI3252069T1/sl unknown
- 2010-07-07 JP JP2012520921A patent/JP5795312B2/ja not_active Expired - Fee Related
- 2010-07-07 PL PL10735198T patent/PL2432798T3/pl unknown
- 2010-07-07 EP EP17176265.1A patent/EP3272763A1/de not_active Withdrawn
- 2010-07-07 HU HUE12194455A patent/HUE037339T2/hu unknown
- 2010-07-07 PT PT17176264T patent/PT3252069T/pt unknown
- 2010-07-07 PT PT121944557T patent/PT2623510T/pt unknown
- 2010-07-07 ES ES10735198T patent/ES2416461T3/es active Active
- 2010-07-07 EP EP17176264.4A patent/EP3252069B1/de active Active
- 2010-07-07 KR KR1020127001509A patent/KR101687853B1/ko active IP Right Grant
- 2010-07-07 DK DK10735198.3T patent/DK2432798T3/da active
- 2010-07-07 PL PL17176264T patent/PL3252069T3/pl unknown
- 2010-07-07 PL PL12194455T patent/PL2623510T3/pl unknown
- 2010-07-07 US US13/376,512 patent/US20120149670A1/en not_active Abandoned
- 2010-07-07 ME MEP-2013-69A patent/ME01534B/me unknown
- 2010-07-07 MX MX2012000930A patent/MX2012000930A/es active IP Right Grant
- 2010-07-07 AU AU2010275849A patent/AU2010275849B2/en not_active Ceased
- 2010-07-07 SI SI201031582T patent/SI2623510T1/sl unknown
- 2010-07-07 UA UAA201201277A patent/UA106502C2/uk unknown
- 2010-07-07 WO PCT/EP2010/004149 patent/WO2011009531A2/de active Application Filing
- 2010-07-07 NO NO12194455A patent/NO2623510T3/no unknown
- 2010-07-07 ES ES12194455.7T patent/ES2648292T3/es active Active
- 2010-07-07 NZ NZ623417A patent/NZ623417A/en not_active IP Right Cessation
- 2010-07-07 KR KR1020167020690A patent/KR101854059B1/ko active IP Right Grant
- 2010-07-07 BR BR112012001344A patent/BR112012001344B8/pt not_active IP Right Cessation
- 2010-07-07 IN IN598DEN2012 patent/IN2012DN00598A/en unknown
- 2010-07-07 SG SG2012000725A patent/SG177519A1/en unknown
- 2010-07-07 MA MA34552A patent/MA33445B1/fr unknown
- 2010-07-07 NZ NZ597639A patent/NZ597639A/en not_active IP Right Cessation
- 2010-07-07 PT PT107351983T patent/PT2432798E/pt unknown
- 2010-07-07 PE PE2016002208A patent/PE20170084A1/es unknown
- 2010-07-07 RS RS20130259A patent/RS52811B/en unknown
- 2010-07-07 SG SG10201404159VA patent/SG10201404159VA/en unknown
- 2010-07-07 EA EA201301263A patent/EA025150B1/ru not_active IP Right Cessation
- 2010-07-07 EP EP12194455.7A patent/EP2623510B1/de active Active
- 2010-07-07 CR CR20170091A patent/CR20170091A/es unknown
- 2010-07-07 DK DK17176264.4T patent/DK3252069T3/da active
- 2010-07-07 CN CN201080032941.3A patent/CN102482317B/zh active Active
- 2010-07-07 CA CA2768407A patent/CA2768407C/en active Active
- 2010-07-07 SG SG10201811830PA patent/SG10201811830PA/en unknown
- 2010-07-07 MY MYPI2012000105A patent/MY179447A/en unknown
- 2010-07-07 EA EA201200121A patent/EA021946B1/ru not_active IP Right Cessation
- 2010-07-07 PE PE2012000076A patent/PE20121085A1/es active IP Right Grant
- 2010-07-09 TW TW099122758A patent/TWI505830B/zh active
- 2010-07-16 UY UY0001032791A patent/UY32791A/es not_active Application Discontinuation
- 2010-07-18 JO JOP/2010/0255A patent/JO3009B1/ar active
- 2010-07-20 AR ARP100102636A patent/AR077491A1/es active IP Right Grant
-
2011
- 2011-12-13 US US13/324,912 patent/US8278469B2/en active Active
- 2011-12-14 IL IL216967A patent/IL216967B/en active IP Right Grant
-
2012
- 2012-01-19 TN TNP2012000028A patent/TN2012000028A1/en unknown
- 2012-01-20 MX MX2013006080A patent/MX338217B/es unknown
- 2012-01-20 HN HN2012000137A patent/HN2012000137A/es unknown
- 2012-01-20 GT GT201200012A patent/GT201200012A/es unknown
- 2012-01-20 EC EC2012011616A patent/ECSP12011616A/es unknown
- 2012-01-20 CR CR20120040A patent/CR20120040A/es unknown
- 2012-01-20 DO DO2012000015A patent/DOP2012000015A/es unknown
- 2012-01-20 CU CU2012000012A patent/CU20120012A7/es active IP Right Grant
- 2012-01-20 CL CL2012000166A patent/CL2012000166A1/es unknown
- 2012-01-20 CO CO12008148A patent/CO6491067A2/es active IP Right Grant
- 2012-02-17 ZA ZA2012/01222A patent/ZA201201222B/en unknown
- 2012-11-30 HK HK12112380.9A patent/HK1171456A1/xx not_active IP Right Cessation
-
2013
- 2013-06-18 HR HRP20130558AT patent/HRP20130558T1/hr unknown
- 2013-06-26 CY CY20131100516T patent/CY1114260T1/el unknown
-
2015
- 2015-05-27 JP JP2015107399A patent/JP2015178522A/ja not_active Withdrawn
- 2015-06-04 US US14/731,232 patent/US9717739B2/en active Active
- 2015-11-12 DO DO2015000276A patent/DOP2015000276A/es unknown
-
2016
- 2016-03-28 JO JOP/2016/0059A patent/JO3732B1/ar active
-
2017
- 2017-02-06 JP JP2017019347A patent/JP6130087B1/ja not_active Expired - Fee Related
- 2017-04-04 US US15/478,803 patent/US10155004B2/en active Active
- 2017-11-21 HR HRP20171805TT patent/HRP20171805T1/hr unknown
- 2017-11-23 CY CY20171101228T patent/CY1119661T1/el unknown
-
2018
- 2018-06-22 EC ECSENADI201847708A patent/ECSP18047708A/es unknown
-
2019
- 2019-06-12 HR HRP20191049TT patent/HRP20191049T1/hr unknown
- 2019-06-12 CY CY20191100611T patent/CY1121926T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171805T1 (hr) | Derivati 17-hidroksi-17-pentafluoroetil-estra-4,9(10)-dien-11-arila, postupci za njihovu proizvodnju i njihova upotreba za liječenje bolesti | |
US9096639B2 (en) | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases | |
HRP20211124T1 (hr) | TETRAHIDRO-1H-PIRIDO[3,4-b]INDOL ANTI-ESTROGENI LIJEKOVI | |
JP2014530191A5 (hr) | ||
DE602005016929D1 (de) | Liganden für den cannabinoidrezeptoren | |
BR112015018882B1 (pt) | Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo | |
JP5865845B2 (ja) | プロゲステロン受容体アンタゴニスト | |
TNSN06033A1 (en) | Piperazine derivatives and their use as therapeutic agents | |
UA115576C2 (uk) | Похідні бензимідазолу як антагоністи ер4 | |
RS89504A (en) | 5-(2-hidroxy-3-/1-(3-trifluoromethylphenyl)-cyclopropyl/-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use ine fertility control and hormone replacement therapy | |
NO20073257L (no) | 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same | |
DE102009034366A1 (de) | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten | |
CN103957921A (zh) | 18-甲基-6,7-亚甲基-3-氧代-17-孕甾-4-烯-21,17β-碳内酯、包含所述化合物的药物制剂及其在治疗子宫内膜异位症中的用途 | |
WO2015091475A1 (de) | Benzimidazolderivate als ep4-liganden | |
JP2013504531A (ja) | 抗癌薬としての置換(ヘテロアリールメチル)チオヒダントイン | |
MX2022016343A (es) | Esteroides neuroactivos y composiciones de estos. | |
EP3749640A1 (en) | Inhibitors of the wnt/beta-catenin pathway | |
EP3558316A1 (de) | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind | |
WO2017025989A1 (en) | Method of wound healing | |
HRP20120952T1 (hr) | 8-beta-supstituirani 16alfa-fluoro-estratrieni kao selektivno aktivni estrogeni | |
HRP960015A2 (en) | Substituted indole derivatives | |
ECSP10010318A (es) | Derivado de -lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene | |
TH120365A (th) | อนุพันธ์ 17-ไฮดรอกซิ-17-เพนตะฟลูออโรเอธิล-เอสตรา-4,9(10)-ไดเอน-11-แอริล,วิธีการของการผลิตสารเหล่านี้และการใช้สารเหล่านี้สำหรับรักษาโรค | |
TH120365B (th) | อนุพันธ์ 17-ไฮดรอกซิ-17-เพนตะฟลูออโรเอธิล-เอสตรา-4,9(10)-ไดเอน-11-แอริล,วิธีการของการผลิตสารเหล่านี้และการใช้สารเหล่านี้สำหรับรักษาโรค | |
NO20082254L (no) | Behandling av stressurininkontinens og blandet urininkontinens |